A Local Approach to Androgenetic Alopecia.
AV^2 is aevX Bio’s investigational long-acting local therapy for androgenetic alopecia, designed to deliver sustained androgen-modulating activity within the scalp while minimising systemic exposure.
By combining established androgen biology with PLGA microsphere drug delivery, aevX aims to separate local therapeutic activity from systemic exposure.
Local delivery.
Local action.
Sustained activity.
aevX Microsphere Technology
Local delivery
PLGA microspheres encapsulating an androgen-modulating agent, delivered subcutaneously to the scalp
Sustained release
Slow, controlled release of the active agent designed to last for months
Local action
Designed to keep androgen modulation in the scalp and limit systemic exposure
Reduced burden
Lifting the burden of daily treatment while reducing the risk of physiological and mental health side effects
Targeting the Biology Where It Matters
Androgenetic alopecia is driven in part by the effects of dihydrotestosterone (DHT) on susceptible hair follicles.
Current androgen-modulating therapies demonstrate the relevance of this pathway, but systemic administration also affects DHT beyond the scalp.